Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
| Line item | THREE MONTHS ENDED JUNE 30, 2026 | THREE MONTHS ENDED JUNE 30, 2025 | SIX MONTHS ENDED JUNE 30, 2026 | SIX MONTHS ENDED JUNE 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development (including related party amounts of $13, $27, $26, and $50, respectively) | 21,925 | 17,861 | 41,237 | 34,914 |
| General and administrative | 4,965 | 4,949 | 10,083 | 10,068 |
| Total operating expenses | 26,890 | 22,810 | 51,320 | 44,982 |
| Loss from operations | (26,890) | (22,810) | (51,320) | (44,982) |
| Other income, net: | ||||
| Interest income | 1,886 | 1,561 | 2,798 | 3,425 |
| Other (expense) income, net | (1) | (5) | 1 | (8) |
Item 1. Financial Statements
FAQ
- What is Artiva Biotherapeutics, Inc.'s G&A?
- Artiva Biotherapeutics, Inc. (ARTV) reported G&A of $4.97M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s G&A changed year-over-year?
- Artiva Biotherapeutics, Inc.'s G&A increased by 0.3% year-over-year, from $4.95M to $4.97M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s G&A?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s G&A has grown at a 20.7% compound annual growth rate (CAGR), from $13.91M to $20.27M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Artiva Biotherapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude